坎格瑞洛对直接PCI的STEMI患者梗死面积的影响:PITRI随机对照试验
PITRI为2期多中心双盲安慰剂对照试验,在口服替格瑞洛基础上,直接PCI前给予坎格瑞洛或安慰剂。164例完成急性心脏磁共振,两组急性梗死面积、微血管阻塞发生率与范围均无显著差异,48小时内均无BARC大出血。
要点
- 直接PCI时给予坎格瑞洛未缩小急性梗死面积。
- 坎格瑞洛未降低微血管阻塞发生率或范围。
- 坎格瑞洛虽显著降低血小板反应性,但未转化为心肌获益。
核心结论
- 在口服替格瑞洛的STEMI患者中,直接PCI时给予坎格瑞洛未减少急性梗死面积或预防微血管阻塞。
研究设计与样本
- 209例入组,164例(78%)完成急性心脏磁共振扫描。
- 在直接PCI前于口服替格瑞洛基础上随机给予坎格瑞洛或安慰剂。
主要发现
- 急性梗死面积:安慰剂14.9%[7.3-22.6]%LVmass vs 坎格瑞洛16.3[9.9-24.4]%LVmass,P=0.40。
- 微血管阻塞发生率:安慰剂48% vs 坎格瑞洛47%,P=0.99。
- 微血管阻塞范围:安慰剂1.63[0.60-4.65]%LVmass vs 坎格瑞洛1.18[0.53-3.37]%LVmass,P=0.46。
- 坎格瑞洛使血小板反应性降低2倍。
- 48小时内两组均无BARC定义的大出血事件。
关键数值与推荐
- 主要疗效终点为首次一周内心脏磁共振测得的急性梗死面积(%LVmass)。
- 微血管阻塞定义为晚期钆增强区内低强化暗核心区域。
- 主要安全终点为48小时内BARC定义的大出血。
临床怎么用
- 对于接受直接PCI且已口服替格瑞洛的STEMI患者,不应期待坎格瑞洛带来缩小梗死面积或减少微血管阻塞的获益。
局限性
- 仅78%入组患者完成急性心脏磁共振扫描。
- 研究为2期试验,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The administration of intravenous cangrelor at reperfusion achieves faster onset of platelet P2Y12 inhibition than oral ticagrelor and has been shown to reduce myocardial infarction (MI) size in the preclinical setting. We hypothesized that the administration of cangrelor at reperfusion will reduce MI size and prevent microvascular obstruction in patients with ST-segment-elevation MI undergoing primary percutaneous coronary intervention. METHODS: This was a phase 2, multicenter, randomized, double-blind, placebo-controlled clinical trial conducted between November 2017 to November 2021 in 6 cardiac centers in Singapore. Patients were randomized to receive either cangrelor or placebo initiated before the primary percutaneous coronary intervention procedure on top of oral ticagrelor. The key exclusion criteria included presenting <6 hours of symptom onset; previous MI and stroke or transient ischemic attack; on concomitant oral anticoagulants; and a contraindication for cardiovascular magnetic resonance. The primary efficacy end point was acute MI size by cardiovascular magnetic resonance within the first week expressed as percentage of the left ventricle mass (%LVmass). Microvascular obstruction was identified as areas of dark core of hypoenhancement within areas of late gadolinium enhancement. The primary safety end point was Bleeding Academic Research Consortium-defined major bleeding in the first 48 hours. Continuous variables were compared by Mann-Whitney U test (reported as median [first quartile-third quartile]), and categorical variables were compared by Fisher exact test. A 2-sided P<0.05 was considered statistically significant. RESULTS: Of 209 recruited patients, 164 patients (78%) completed the acute cardiovascular magnetic resonance scan. There were no significant differences in acute MI size (placebo, 14.9% [7.3-22.6] %LVmass versus cangrelor, 16.3 [9.9-24.4] %LVmass; P=0.40) or the incidence (placebo, 48% versus cangrelor, 47%; P=0.99) and extent of microvascular obstruction (placebo, 1.63 [0.60-4.65] %LVmass versus cangrelor, 1.18 [0.53-3.37] %LVmass; P=0.46) between placebo and cangrelor despite a 2-fold decrease in platelet reactivity with cangrelor. There were no Bleeding Academic Research Consortium-defined major bleeding events in either group in the first 48 hours. CONCLUSIONS: Cangrelor administered at the time of primary percutaneous coronary intervention did not reduce acute MI size or prevent microvascular obstruction in patients with ST-segment-elevation MI given oral ticagrelor despite a significant reduction of platelet reactivity during the percutaneous coronary intervention procedure. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03102723.
引用
- Bulluck, Chong, Bryant, et al. Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial). Circulation. 2024. PMID: 38742915. doi:10.1161/CIRCULATIONAHA.124.068938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。